The approval of sunitinib, sorafenib and temsirolimus has dramatically altered the management of renal cell carcinoma (RCC) • Karnofsky performance status (KPS) <80;
• serum calcium >10 (corrected for albumin);
• haemoglobin below normal;
• absence of prior nephrectomy; and
• lactate dehydrogenase (LDH) >1.5 x upper limit of normal. 1 The median survivals were 20, 10 and four months for good-(no risk factors), intermediate-(one to two risk factors) and poor-risk patients (three or more risk factors), respectively. In another analysis at MSKCC, similar adverse prognostic factors emerged, although absence of nephrectomy was replaced by less than one year from initial diagnosis to start of therapy. 2 The MSKCC criteria were validated in a separate data set at the Cleveland Clinic, and in addition to four of the five MSKCC criteria (excluding KPS), prior radiotherapy and presence of hepatic, lung and retroperitoneal nodal metastases were found to be prognostic factors. 3 Using the number of metastatic sites as a surrogate for individual sites (zero to one versus two to three), MSKCC risk groups were expanded to accommodate these two additional prognostic factors. Similar prognostic factors were also subsequently demonstrated to be important for cytokine-pre-treated patients in an analysis from MSKCC. 4 
Update of Current Systemic Therapy for

Renal Cell Carcinoma
Sunitinib Malate
Sunitinib, a multitargeted tyrosine kinase inhibitor (TKI), was compared with IFN-α in the front-line setting in a trial of 750 patients with clear-cell RCC (see Table 1 ). 5, 6 Sunitinib yielded a significantly longer median progressionfree survival (PFS) (11 versus 5.1 months) and response rate (RR) (39 versus 8%) . Almost all responses were partial responses, and all risk groups appeared to benefit, although the poor-risk subset included only a small cohort of patients. In a recent update, the median overall survivial (OS) imporved with sunitinib (26.4 versus 21.8 months; p=0.051). 6 On censoring patients who crossed over from IFN to sunitinib, the difference in survival respectively. Thyroid function abnormalities appear to be common, and routine monitoring is warranted. 7 Based on these data, IFN-α has been supplanted by sunitinib as the reference standard for advanced clear-cell RCC. Sunitinib has also been demonstrated in separate phase II trials to have significant activity following prior therapy with cytokines or bevacizumab. [8] [9] [10] 
Bevacizumab
The AVastin for Renal Cell Cancer (AVOREN) trial randomised 649 previously untreated patients with a significant clear-cell component (>50%) to front- Table 1 ). 11 The addition of bevacizumab to IFN-α 2a significantly increased median PFS Bevacizumab plus IFN had a higher objective RR (25.5 versus 13.1%; p<0.0001) and exhibited expected but manageable toxicities. Given the PFS reported in a previous trial of bevacizumab alone of 8.5 months in the front-line setting, the value of adding IFN-α 2a is unclear. 13 Following cytokines, the RR with a similar dose of single-agent bevacizumab (10mg/kg every two weeks) was 10%, with a median time to progression of 4.8 months. 14 
Temsirolimus
In a randomised phase II trial of three different doses of the mammalian target of rapamycin (mTOR) inhibitor temsirolimus in the setting of prior cytokine therapy, in most patients an objective RR of 7% and a minor response rate of 26% was observed. Median time to tumour progression was 5.8 months and median survival was 15.0 months. Intermediate-and poor-risk patients appeared to selectively benefit compared with historical controls. 15 Temsirolimus, IFN-α 2a and combination temsirolimus plus IFN-α 2a were compared in a subsequent 626-patient phase III trial that selected patients with poor-risk RCC (see Table 1 ). 16 At least three of the following six poor prognostic factors were required:
• serum LDH >1.5 times the upper limit of the normal;
• haemoglobin level below the lower limit of normal;
• corrected serum calcium level >10mg/decilitre;
• less than one year from initial diagnosis to randomisation;
• KPS of 60 or 70; and
• metastases in multiple organs. The most common grade 3-4 adverse effects of temsirolimus were asthaenia (11%), rash (4%), anaemia (20%), nausea (2%), dyspnoea However, secondary analysis censoring cross-over data showed a significant OS benefit for sorafenib (HR 0.78; p=0.0287), since patients received benefit from sorafenib upon cross-over. 18 Severe grade 3-4 diarrhoea, rash, fatigue, hypertension and hand-foot skin reactions occurred in a small proportion (1-6%) of patients with sorafenib.
A smaller randomised phase II trial in the front-line setting did not demonstrate improved outcomes with sorafenib compared with IFN-α. 19 Sorafenib is an active agent, but is increasingly reserved for salvage therapy following other agents given the lack of robust front-line data (see Table 2 ).
In a recently reported phase II trial, 27 evaluable patients with clear-cell RCC refractory to either bevacizumab (n=11) or sunitinib (n=16) were treated with sorafenib. 20 No objective responses have been observed, although nine patients (33%) had >5% decrease in tumour burden, with a median PFS of 3.7 months. Interestingly, there was no association between tumour shrinkage and response to prior therapy. Toxicities were significant, with grade 3 toxicities experienced by 67% of patients. Other retrospective reports support the presence of only partial cross-resistance between available novel anti-angiogenic agents. [21] [22] [23] Hence, a rationale can generally be made for continued targeting of angiogenesis with a sequence of different agents (see Table 2 ).
Everolimus
A phase III trial of a novel oral mammalian target of rapamycin (mTOR) kinase inhibitor, everolimus (RAD-001), versus placebo was completed with a 2:1 randomisation. 24 These data were presented at the American Society Additionally, all risk groups appeared to benefit. Everolimus exhibited a favourable toxicity profile, with a low incidence of myelosuppression and a low incidence of grade 3-4 non-haematological toxicities (12% hyperglycaemia, 4% hypophosphataemia, 3% hypercholesteroleamia, stomatitis, pneumonitis, infections and fatigue). Based on these data, everolimus should be considered a standard for patients with progressive clear-cell RCC following prior TKIs, and formal approval by regulatory agencies is awaited.
High-dose Interleukin-2
High-dose (HD) IL-2 has been employed for metastatic RCC based on a small fraction (~7%) of patients who demonstrate durable complete remission (CR) and apparent cures. 25 Clinical trials have demonstrated improved objective RRs and response duration when HD IL-2 was compared with other administration schedules of IL-2 and IFN. 26, 27 However, no randomised trial has demonstrated an overall survival 
Role of Cytoreductive Nephrectomy
Randomised trials have demonstrated a significant survival advantage in metastatic RCC with cytoreductive nephrectomy followed by IFN-α. 32, 33 Retrospective reviews also suggest that this approach may improve outcomes in patients receiving HD IL-2. 34 The vast majority of patients accrued on trials with novel TKIs had undergone prior nephrectomy.
However, the role of prior nephrectomy in improving outcomes in the era of novel highly active agents remains to be defined.
The paradigm of pre-surgical systemic therapy followed by cytoreductive nephrectomy may be employed to develop individualised therapy, elucidate Kidney Cancer mechanisms of resistance and develop reliable prognostic and predictive biomarkers. Early data suggest that administration of the novel antiangiogenic agents prior to surgery is not associated with increased perioperative mortality or morbidity. 35 The MD Anderson Cancer Center reported that bevacizumab discontinued at least four weeks before and sorafenib/sunitinib discontinued at least 24 hours before surgery appear feasible. In an ongoing prospective clinical trial at MD Anderson, patients are randomised to upfront surgery followed by sunitinib two weeks after the operation or sunitinib for one to four weeks prior to nephrectomy performed 24 hours after discontinuation of sunitinib, and then followed by resumption of sunitinib. Another randomised trial in France is comparing front-line sunitinib with versus without initial cytoreductive nephrectomy in order to elucidate the value of this procedure with sunitinib therapy.
Therapy of Non-clear-cell Renal Cell Carcinoma
Based on the large randomised trial comparing temsirolimus with IFN demonstrating improved OS and a more profound benefit for the subset with non-clear-cell RCC, temsirolimus may be considered an option for the front-line therapy of non-clear-cell RCC with poor-risk features. 16 In another report, 41 patients with papillary and 12 with chromophobe histologies who received sorafenib or sunitinib were analysed. 36 RR, PFS and OS for the entire cohort were 10%, 8.6 months and 19.6 months, respectively. Three of 12 patients (25%) with chromophobe RCC achieved a response, while two of 41 (4.8%) papillary RCC patients responded. However, these outcomes are clearly suboptimal and a clinical trial is an excellent alternative, notably to evaluate Met inhibitors for papillary RCC (see Table 3 ).
Ongoing Clinical Trials for Advanced Renal Cell Carcinoma
Generally, patients progressing after prior TKIs, bevacizumab or temsirolimus are candidates for clinical trials (see Tables 2 and 3) . The Future of Therapy for Advanced Renal Cell Cancer
Conclusion
The burgeoning list of active agents for the therapy of RCC presents a unique set of challenges. However, the rational selection of currently approved agents for the therapy of patients with RCC in different settings is feasible by implementing evidence-based medicine. Incorporation of risk factor models will enable clinicians to appropriately select patients for specific agents. It is also critical to remember that the vast majority of patients are not cured with currently approved agents, and continued support of clinical trial programmes is essential (see Tables 2 and 3 ). The future for the therapy of RCC appears promising, with the emergence of novel active agents and with a plethora of other exciting agents waiting to be evaluated. ■
Disclosures
Author disclosures are as follows:
• 
